港股異動丨藥明康德(2359.HK)漲逾4% 獲貝萊德增持36.11萬股
格隆匯7月13日丨藥明康德(2359.HK)漲逾4%,報112.2港元,總市值2593.6億港元。7月13日,聯交所最新權益披露資料顯示,7月7日,藥明康德(02359.HK)獲得貝萊德增持36.106萬股,每股均價100.5145港元,涉資約3629.2萬港元。增持後,貝萊德在藥明康德2895.46萬股,持有股份的比例由11.98%上升至12.13%。2020年以來,貝萊德累計對藥明康德進行了3次增持和1次減持。招商證券(香港)7月7日發佈研報稱,隨着二季度中國區復工復產以及需求端持續穩定,相信公司一季度的業績表現已經觸底,更新目標價至111港元,重申“買入”評級。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.